Latest News

View allAccessAL amyloidosisCAR-TConferencesMPEMyelomaNewsPatient evidenceSin categoríaVideos

Promising results of CAR T-Cell therapy in myeloma patients

53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) CHICAGO – In an early clinical trial, 33 out of 35 (94%) patients had clinical remission of myeloma upon receiving a new type of immunotherapy  ̶  chimeric antigen receptor (CAR) T cells targeting B-cell maturation protein or BCMA. Most patients had only mild side effects. The study was presented at the 2017 American Society of Clinical Oncology (ASCO) Annual…

Read more

Patients and cancer experts launch a joint vision for improving cancer outcomes in Europe

A coalition of 60 patient advocates, healthcare professionals and scientists (including 3 Nobel Prize winners) from 20 European countries have come together to publish a blueprint for improving cancer outcomes and achieving better quality of life for cancer survivors throughout Europe.1 They are members of the European Cancer Concord (ECC®), an equal partnership between patients…

Read more

MPE will hold a webinar on ASH 2016 Highlights in myeloma

Myeloma Patients Europe will hold an online webinar to review the most recent myeloma findings presented at the annual meeting of the American Society of Hematology (ASH) that took place in San Diego (California, United States) in December 2016. The talk will be given by Dr Laurent Garderet, Department of Hematology, Saint Antoine Hospital, Paris,…

Read more

Innovative Medicines Initiative (IMI) approves € 40 million project for better care of patients with haematologic malignancies

Brussels/Salamanca, January 9, 2017. The Innovative Medicines Initiative (IMI) has approved HARMONY, a project that aims to foster better access and care for patients with various hematologic malignancies (HM) with the use of big data. The project is made up of 51 partners from 11 European countries, including 7 pharmaceutical companies. Other organisations such as…

Read more

Addition of daratumumab to bortezomib and dexamethasone in patients with relapsed or refractory shows promising results in a phase III trial

At the ESMO 2016 Congress held in Copenhagen between 7th-11th October, Dr Katja Weissel, from the Haematology and Oncology Department of Medicine at University Hospital Tuebingen (Germany), presented the results of the CASTOR study, a phase III randomised controlled study of daratumumab, bortezomib and dexamethasone (DVd) compared with bortezomib and dexamethasone (Vd) in patients with…

Read more
October

November 2026

December
MO
TU
WE
TH
FR
SA
SU
26
27
28
29
30
31
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
1
2
3
4
5
6
Events for 1st November
No Events
Events for 2nd November
No Events
Events for 3rd November
No Events
Events for 4th November
No Events
Events for 5th November
No Events
Events for 6th November
No Events
Events for 7th November
No Events
Events for 8th November
No Events
Events for 9th November
No Events
Events for 10th November
No Events
Events for 11th November
No Events
Events for 12th November
No Events
Events for 13th November
No Events
Events for 14th November
No Events
Events for 15th November
No Events
Events for 16th November
No Events
Events for 17th November
No Events
Events for 18th November
No Events
Events for 19th November
No Events
Events for 20th November
No Events
Events for 21st November
No Events
Events for 22nd November
No Events
Events for 23rd November
No Events
Events for 24th November
No Events
Events for 25th November
No Events
Events for 26th November
No Events
Events for 27th November
No Events
Events for 28th November
No Events
Events for 29th November
No Events
Events for 30th November
No Events